Welcome to our dedicated page for Abcellera Biologics news (Ticker: ABCL), a resource for investors and traders seeking the latest updates and insights on Abcellera Biologics stock.
AbCellera Biologics Inc. (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in endocrinology, women’s health, immunology, and oncology. The ABCL news feed on Stock Titan aggregates company announcements, clinical updates, financial disclosures, and other material events drawn from AbCellera’s press releases and regulatory filings.
Investors and followers of ABCL can use this page to review news on AbCellera’s internal pipeline, including its lead programs ABCL635 and ABCL575. Recent announcements describe ABCL635 as a potential first-in-class non-hormonal antibody treatment for moderate-to-severe vasomotor symptoms associated with menopause, now in a Phase 1/2 clinical trial, and ABCL575 as an Fc-silenced, half-life extended investigational antibody therapy in a Phase 1 study for moderate-to-severe atopic dermatitis with potential applications in other inflammatory and autoimmune conditions.
The ABCL news stream also captures business and corporate developments, such as quarterly business results, updates on partner-initiated programs and molecules in the clinic, and changes in leadership and board composition. In addition, it includes disclosures on legal and intellectual property matters, including AbCellera’s settlement and patent license agreement with Bruker Corporation that resolved patent litigation globally and provides for upfront and royalty payments.
By reviewing this curated news page, readers can follow how AbCellera advances its antibody discovery and development engine, expands its clinical-stage pipeline, and manages its partnered programs and intellectual property. Bookmark this ABCL news section to quickly access company-issued updates, earnings announcements, clinical trial milestones, and other material information relevant to AbCellera’s operations and strategy.
AbCellera has unveiled promising preclinical data for its PSMA x CD3 T-cell engagers (TCEs) at the AACR Annual Meeting 2025. The research focuses on potential treatments for metastatic castration-resistant prostate cancer (mCRPC).
Key findings include:
- Potent tumor-cell killing ability, with one molecule showing ~10x higher EC50 than benchmark
- Sustained activity across four rounds of serial T-cell killing
- Significant tumor growth inhibition in xenograft mouse models
- Enhanced potency potential when combined with costimulatory PSMA x CD28 bispecifics
This marks the first demonstration of AbCellera's novel CD3-binders generating molecules with strong anti-tumor efficacy in vivo. The company's TCE platform strategy combines diverse CD3 and tumor-binding antibodies to develop optimized therapeutic candidates.
AbCellera (Nasdaq: ABCL) has announced its upcoming participation in two major investor conferences. The company will attend the Bloom Burton & Co. Healthcare Investor Conference scheduled for May 5-6, and the Goldman Sachs 46th Annual Global Healthcare conference taking place June 9-11. Interested parties can find more details on AbCellera's Investor Relations website.
AbCellera (ABCL) has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025. The company will host an earnings conference call on the same day at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). Investors can access a live audio webcast of the earnings call through AbCellera's Investor Relations website, where a replay will also be made available after the conference.
AbCellera (ABCL) has announced an upcoming poster presentation at the American Association for Cancer Research (AACR) 116th Annual Meeting in Chicago. The presentation will showcase preclinical in vivo data on the company's PSMA x CD3 T-cell engagers for prostate cancer treatment.
The poster presentation, titled 'PSMA x CD3 T-cell engagers show preclinical efficacy for the treatment of prostate cancer' (Abstract #6012), will be presented in the Therapeutic Antibodies session on Tuesday, April 29, from 2:00 p.m. to 5:00 p.m. CDT at Section 35, Board 7 of the McCormick Place Convention Center.
AbCellera (ABCL) reported its full year 2024 financial results, marking a transition from a platform company to a clinical-stage biotech. The company recorded $28.8 million in total revenue, down from $38.0 million in 2023, and posted a net loss of $162.9 million ($0.55 per share) compared to $146.4 million loss in 2023.
Key operational highlights include reaching 96 partner-initiated programs (up from 87 in 2023) and advancing three additional molecules to the clinic, bringing the total to 16 clinical-stage molecules. The company maintains a strong liquidity position of $840 million, comprising $652.9 million in cash and equivalents plus $186 million in available non-dilutive government funding.
R&D expenses were $167.3 million, while G&A expenses increased to $72.7 million. The company is preparing to initiate Phase 1 trials for two programs, ABCL635 and ABCL575, and plans to start activities in its new clinical manufacturing facility in 2025.
AbCellera (ABCL) has announced its participation in two major investor conferences in March. The company will attend the 45th Annual TD Cowen Health Care Conference scheduled for March 3-5, and the KeyBanc Capital Markets Healthcare Forum taking place March 18-19. Interested parties can find more details on AbCellera's Investor Relations website.
AbCellera (Nasdaq: ABCL) has announced it will release its full year 2024 financial results on Thursday, February 27, 2025. The company will host an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) on the same day. Investors can access a live audio webcast of the earnings call through AbCellera's Investor Relations website, where a replay will also be available after the conference.
AbCellera (ABCL) has expanded its collaboration with AbbVie (ABBV) to develop novel T-cell engagers (TCE) in oncology, building upon their partnership from December 2022. The expanded agreement gives AbbVie access to AbCellera's TCE platform for developing therapeutic antibodies targeting tumors.
Under the agreement terms, AbCellera will lead discovery activities while AbbVie retains development and commercialization rights for resulting therapeutic antibodies. AbCellera will receive upfront and research payments, plus potential downstream milestone payments and tiered royalties on net sales.
AbCellera (ABCL) has announced its participation in two major upcoming investor conferences. The company will present at the Piper Sandler 36th Annual Healthcare Conference in New York on December 3, 2024, at 11:30 a.m. PT, and at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on January 15, 2025, at 4:30 p.m. PT.
Both presentations will be accessible via live audio webcasts through links on AbCellera's Investor Relations website, with replay options available after the events.
AbCellera (Nasdaq: ABCL) presented new data on its T-cell engager (TCE) platform at the SITC 39th Annual Meeting in Houston. The presentation showcases strategies for TCE development, including CD3-binding antibodies for enhanced tumor-cell killing and optimal cytokine release. The company highlighted molecules designed to improve efficacy in solid tumor treatment through T-cell activation and proliferation via CD28 and 4-1BB costimulation. The data includes preclinical characterization of TCEs targeting B7-H4 and PSMA solid tumor targets, demonstrating distinctive tumor-cell killing and cytokine release profiles compared to clinical benchmarks.